KRAS and lung carcinoma: Conversely, the fluorescence intensity of CRISPR–Cas12a with crRNAs specific to wild-type KRAS increased with the reaction time in the wild-type KRAS DNA; however, this did not cause a change in the fluorescence intensity in DNA of the lung cancer cell lines that had the KRAS mutations (Figure 2D).